Related references
Note: Only part of the references are listed.Integrating the Immunome in the Stratification of Myelodysplastic Syndromes and Future Clinical Trial Design
Susann Winter et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Single-cell Analysis of CAR-T Cell Activation Reveals A Mixed TH1/TH2 Response Independent of Differentiation
Iva Xhangolli et al.
GENOMICS PROTEOMICS & BIOINFORMATICS (2019)
The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy
Lourdes M. Mendez et al.
FRONTIERS IN ONCOLOGY (2019)
Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression
Anastasiya Kazachenka et al.
GENOME MEDICINE (2019)
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
Thomas A. Mace et al.
GUT (2018)
AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo
A. Unnikrishnan et al.
LEUKEMIA (2018)
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Nucleosidic DNA demethylating epigenetic drugs - A comprehensive review from discovery to clinic
Khushboo Agrawal et al.
PHARMACOLOGY & THERAPEUTICS (2018)
CD4+ T cell help in cancer immunology and immunotherapy
Jannie Borst et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity
Hirotake Tsukamoto et al.
CANCER SCIENCE (2018)
IL6 Signaling in Peripheral Blood T Cells Predicts Clinical Outcome in Breast Cancer
Lei Wang et al.
CANCER RESEARCH (2017)
Immunological effects of hypomethylating agents
Katherine E. Lindblad et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes
Ashwin Unnikrishnan et al.
CELL REPORTS (2017)
JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
Chunwan Lu et al.
ONCOIMMUNOLOGY (2017)
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Matthew H. Spitzer et al.
CELL (2017)
The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine
Paraskevi Miltiades et al.
CLINICAL CANCER RESEARCH (2016)
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
Andreas D. Orskov et al.
ONCOTARGET (2015)
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
A. Valencia et al.
LEUKEMIA (2014)
Cancer Immunotherapy Based on Mutation-Specific CD4+T Cells in a Patient with Epithelial Cancer
Eric Tran et al.
SCIENCE (2014)
The two faces of IL-6 in the tumor microenvironment
Daniel T. Fisher et al.
SEMINARS IN IMMUNOLOGY (2014)
5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies
A. O. Gang et al.
BLOOD CANCER JOURNAL (2014)
FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report
Michele S. Redell et al.
BLOOD (2013)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome
Benedetta Costantini et al.
HAEMATOLOGICA (2013)
Single-Cell Network Profiling of Peripheral Blood Mononuclear Cells from Healthy Donors Reveals Age- and Race-Associated Differences in Immune Signaling Pathway Activation
Diane M. Longo et al.
JOURNAL OF IMMUNOLOGY (2012)
Azacitidine differentially affects CD4pos T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes
Hetty J. Bontkes et al.
LEUKEMIA RESEARCH (2012)
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
Raphael Itzykson et al.
BLOOD (2011)
Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML
James Marvin et al.
BLOOD (2011)
Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy
Shikhar Aggarwal et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Th17 and Foxp3+ T regulatory cell dynamics and distribution in myelodysplastic syndromes
Irene Bouchliou et al.
CLINICAL IMMUNOLOGY (2011)
Genomic views of STAT function in CD4+ T helper cell differentiation
John J. O'Shea et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting
Luis I. Sanchez-Abarca et al.
BLOOD (2010)
In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia
Jaebok Choi et al.
BLOOD (2010)
Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage
Roberta Mortarini et al.
CLINICAL CANCER RESEARCH (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplasticsyndromes (MDS)
I. Kotsianidis et al.
LEUKEMIA (2009)
Mechanisms of Disease: Myelodysplastic Syndromes.
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Impaired interferon signaling is a common immune defect in human cancer
Rebecca J. Critchley-Thorne et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease
Hong Zheng et al.
BLOOD (2008)
Epigenetic drugs as pleiotropic agents in cancer treatment:: Biomolecular aspects and clinical applications
Luca Sigalotti et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2007)
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)
Shahram Y. Kordasti et al.
BLOOD (2007)
CD4 cells can be more efficient at tumor rejection than CD8 cells
Ainhoa Perez-Diez et al.
BLOOD (2007)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
M Kortylewski et al.
NATURE MEDICINE (2005)
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells
CA Klebanoff et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Single cell profiling of potentiated phospho-protein networks in cancer cells
JM Irish et al.
CELL (2004)
SOCS3 negatively regulates IL-6 signaling in vivo
BA Croker et al.
NATURE IMMUNOLOGY (2003)
The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex
SA Jones et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2002)
Share Paper
